What is HC Wainwright’s Estimate for GANX FY2024 Earnings?

Gain Therapeutics, Inc. (NASDAQ:GANX) – Stock analysts at HC Wainwright boosted their FY2024 earnings estimates for Gain Therapeutics in a research report issued on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.95) per share for the year, up from their prior forecast of ($1.06). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2024 earnings at ($0.18) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.68) EPS.

GANX has been the topic of a number of other research reports. Chardan Capital reissued a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a report on Friday, August 9th. Oppenheimer reiterated an “outperform” rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Wednesday, August 14th.

Gain Therapeutics Trading Down 4.9 %

Gain Therapeutics stock opened at $1.73 on Wednesday. Gain Therapeutics has a 1 year low of $0.89 and a 1 year high of $5.33. The firm’s 50-day moving average is $2.07 and its 200-day moving average is $1.71. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The company has a market cap of $45.88 million, a P/E ratio of -1.57 and a beta of 0.33.

Institutional Investors Weigh In On Gain Therapeutics

Large investors have recently made changes to their positions in the company. Warberg Asset Management LLC acquired a new stake in Gain Therapeutics in the 2nd quarter valued at approximately $66,000. Renaissance Technologies LLC increased its holdings in shares of Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after purchasing an additional 72,000 shares during the period. Geode Capital Management LLC increased its holdings in shares of Gain Therapeutics by 48.0% during the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after purchasing an additional 88,236 shares during the period. Finally, Hohimer Wealth Management LLC bought a new stake in shares of Gain Therapeutics during the second quarter valued at about $422,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.